Medpage Today on MSN14h
Myasthenia Gravis Patients May Use Less Steroids After Starting EfgartigimodSAVANNAH, Ga. -- One year after starting efgartigimod (Vyvgart) treatment, most generalized myasthenia gravis (gMG) patients ...
Medpage Today on MSN2d
Sustained Disease Control in Adolescent Myasthenia Gravis With FcRn BlockerInvestigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be ...
Medpage Today on MSN5d
Nipocalimab Shows Sustained Efficacy in Myasthenia GravisInvestigational nipocalimab lessened disease severity in generalized myasthenia gravis (gMG), the phase III Vivacity-MG3 ...
A first-in-class anti-CD19 B-cell depleting agent was safe and demonstrated superior efficacy vs placebo in patients with ...
The investigational monoclonal antibody nipocalimab is associated with significant improvement in patients with generalized ...
MedPage Today on MSN5d
Anti-CD19 Monoclonal Antibody Shows Positive Results in Myasthenia Gravis"Inebilizumab is a humanized monoclonal antibody that causes targeted and sustained depletion of CD19-positive B cells, ...
Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized ...
Tuesday announced positive topline data from the Phase 3 MINT study evaluating Uplizna for the treatment of adults ...
Amgen said it achieved positive results from a Phase 3 trial of its treatment for adults with generalized myasthenia gravis, a rare autoimmune disorder.
Johnson & Johnson’s (J&J) investigational FcRn blocker nipocalimab has demonstrated sustained disease control in adolescents with the rare autoimmune disease generalised myasthenia gravis (gMG), ...
For immediate release Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback